Optiscan Imaging Limited (AU:OIL) has released an update.
Optiscan Imaging Ltd has announced a productive quarter with strategic advancements in medical imaging technology, including a collaboration with Mayo Clinic to develop a new imaging system for robotic surgery and the unveiling of their InVue™ device for breast cancer surgery. They’ve also achieved ISO 13485:2016 certification, secured grant funds for AI-endomicroscope development, and are progressing with a cloud-based telepathology platform. These developments aim to position Optiscan at the forefront of the expanding digital health and precision surgery markets.
For further insights into AU:OIL stock, check out TipRanks’ Stock Analysis page.
